The Jaguar Health Inc (JAGX) share price is expected to increase by 1218.18% over the next year. This is based on calculating the average 12-month share price estimate provided by 1 stock analysts who have covered JAGX. Price targets range from $14.5 at the low end to $14.5 at the high end. The current analyst consensus for JAGX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 1 Wall Street analysts have assigned JAGX 1 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Jaguar Health Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on JAGX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of JAGX.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Louise Chen Cantor Fitzgerald | Overweight | $5 | Initiates | Jul 7, 2021 |
H.C. Wainwright | Buy | Reiterates | Nov 25, 2020 | |
Ladenburg Thalmann | Buy | Initiates | Nov 25, 2020 | |
Rodman & Renshaw | Buy | Initiates | Nov 25, 2020 | |
Aegis Capital | Buy | Initiates | Nov 25, 2020 | |
HC Wainwright & Co. | Buy | $3 | Reiterates | Nov 18, 2019 |
H.C. Wainwright | Buy | Reiterates | Nov 18, 2019 | |
Ladenburg Thalmann | Buy | Initiates | Sep 12, 2019 | |
Rodman & Renshaw | Buy | Initiates | Jul 11, 2017 | |
Aegis Capital | Buy | Initiates | Nov 12, 2015 |
When did it IPO
2015
Staff Count
49
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Ms. Lisa A. Conte
Market Cap
$10.8M
In 2023, JAGX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that JAGX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.